Search results
Results From The WOW.Com Content Network
PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1046– e1081. DOI: 10.1161/CIR.0000000000000624.
The “2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease” provides an update to and consolidates new evidence since the “2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease” and the corresponding “2014 ACC/AHA ...
Hypertrophic cardiomyopathy remains a common genetic heart disease reported in populations globally. Recommendations from the “2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy” have been updated with new evidence to guide clinicians.
Both guidelines recommend a lower BP target (<130/80 mm Hg) for adults at high risk to reduce the risk of CV events. Key differences include a lower diagnostic threshold by ACC/AHA criteria (<130/80 mm Hg) than by ESH criteria (<140/90 mm Hg) and age-based treatment targets (ESH criteria).
Hypertriglyceridemia is associated with increased cardiovascular risk and pancreatitis (especially in patients with triglyceride levels ≥500 mg/dL). Therefore, treatment of persistent hypertriglyceridemia beyond statin therapy and nonstatin LDL-C–lowering therapies may be warranted in patients with clinical ASCVD and LDL-C ≥190 mg/dL.
The Dyslipidemia Clinical Topic Collection gathers the latest guidelines, news, JACC articles, education, meetings and clinical images pertaining to its cardiovascular topical area — all in one place for your convenience.
In secondary prevention, the guidelines group patients according to their risk (high risk vs very high risk) and incorporate new nonstatin therapies as add-on, evidence-based treatment options when low-density lipopro-tein (LDL-C) remains above the 70 mg/dL threshold.
Since the 2013 ACC/AHA cholesterol guideline, newer cholesterol-lowering agents (non-statin drugs) have been introduced and subjected to randomized controlled trials, including ezetimibe and PCSK9 inhibitors. Most patients with Atherosclerotic Cardiovascular Disease are treated with statins alone.
The 2018 AHA/ACC Cholesterol Guideline outlines recommendations for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in all age groups. (See companion pocket guide for Secondary Prevention: Managing Blood Cholesterol in Patients at Very High-Risk for Future ASCVD Events.)
SEVERE HYPERCHOLESTEROLEMIA. Based on moderate-quality evidence from RCTs, maximally tolerated statin therapy is recommended for patients 20 to 75 years of age with an LDL-C level of 190 mg per dL...